Home › Funds › JW Asset Management, LLC › CPRX
JW Asset Management, LLC position in CPRX
CATALYST PHARMACEUTICALS INC
JW Asset Management, LLC reported holding 388,392 shares of CPRX (CATALYST PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$12.2M, representing 3.82% of its reported portfolio and ranking #4 among its reported holdings. JW Asset Management, LLC has disclosed CPRX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How JW Asset Management, LLC's CPRX position evolved
JW Asset Management, LLC first disclosed a stake in CPRX in Q3 2023 at 563,392 shares (US$6.6M). The position peaked in Q2 2026 at 388,392 shares, worth US$12.2M. Across 12 filings, JW Asset Management, LLC increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 9 time(s). The most recent filing (Q2 2026) shows 388,392 shares valued at US$12.2M. Notable position changes include a 27% trim in Q4 2023.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 563.39K | $6.59M | New |
| Q4 2023 | 413.39K | $6.95M | Reduce |
| Q1 2024 | 413.39K | $6.59M | Hold |
| Q2 2024 | 413.39K | $6.40M | Hold |
| Q3 2024 | 413.39K | $8.22M | Hold |
| Q4 2024 | 413.39K | $8.63M | Hold |
| Q1 2025 | 413.39K | $10.02M | Hold |
| Q2 2025 | 388.39K | $8.43M | Reduce |
| Q3 2025 | 388.39K | $7.65M | Hold |
| Q4 2025 | 388.39K | $9.07M | Hold |
| Q1 2026 | 388.39K | $9.62M | Hold |
| Q2 2026 | 388.39K | $12.21M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CPRX and 13F data
CPRX (CATALYST PHARMACEUTICALS INC) is a company whose sector is not yet classified in our data. 43 other funds we track also report a position in CPRX — the largest reported positions include GLAZER CAPITAL, LLC (US$113.2M), HBK INVESTMENTS L P (US$88.6M), NEXPOINT ASSET MANAGEMENT, L.P. (US$50.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CPRX
- GLAZER CAPITAL, LLC 3.60M sh · $113.24M · Q2 2026
- HBK INVESTMENTS L P 2.82M sh · $88.64M · Q2 2026
- NEXPOINT ASSET MANAGEMENT, L.P. 1.60M sh · $50.37M · Q2 2026
- Polar Asset Management Partners Inc. 1.15M sh · $36.15M · Q2 2026
- WATER ISLAND CAPITAL LLC 933.82K sh · $29.35M · Q2 2026
- KENNEDY CAPITAL MANAGEMENT LLC 856.61K sh · $26.92M · Q2 2026
- Sagefield Capital LP 569.48K sh · $17.90M · Q2 2026
More on JW Asset Management, LLC
FAQ
How long has JW Asset Management, LLC held CPRX?
JW Asset Management, LLC has disclosed CPRX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is JW Asset Management, LLC's current position in CPRX?
As of Q2 2026, JW Asset Management, LLC holds 388.39K shares of CPRX (CATALYST PHARMACEUTICALS INC), valued at $12.21M, representing 3.82% of its reported portfolio and ranking #4.
Has JW Asset Management, LLC been buying or selling CPRX?
In the latest 13F filing (Q2 2026), JW Asset Management, LLC held unchanged its position in CPRX. The position peaked in Q2 2026 at 388.39K shares.
Which other funds hold CPRX?
Other major institutional holders of CPRX include GLAZER CAPITAL, LLC, HBK INVESTMENTS L P, NEXPOINT ASSET MANAGEMENT, L.P., among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.